Shielding the Joint: New Antimicrobial Coating from India Could Slash Devastating Hip and Knee Implant Infections

MANGALURU, May 26, 2026 — Researchers at the National Institute of Technology Karnataka (NITK) Surathkal have developed a groundbreaking, patented antimicrobial coating for orthopaedic implants that could soon transform outcomes for millions of patients undergoing hip and knee joint replacements. Engineered using an advanced thermal spray process, this indigenous biomedical innovation delivers localized protection against bacteria while simultaneously improving the mechanical durability and bone integration of the implant. Developed under India’s “Make in India” initiative, the technology directly targets one of orthopaedic surgery’s most persistent and expensive complications: implant-associated infections.

The Problem: A Quiet Global Health Crisis on the Implant Surface

Orthopaedic joint replacements are highly successful procedures that restore mobility to millions. However, a persistent threat looms in the operating room. Globally, implant-associated infections occur in 1% to 9% of primary joint replacement surgeries, and those rates nearly double during revision procedures.

The crisis is more pronounced in resource-limited environments. In low- and middle-income countries, surgical site infections (SSIs) affect approximately 11% of surgical patients. The primary culprit is the formation of a “biofilm”—a slimy, protective layer that bacteria build around themselves once they colonize an implant’s surface. Inside a biofilm, bacteria are heavily shielded from traditional systemic antibiotics, often forcing surgeons to perform complex, multi-stage operations to completely remove and replace the infected hardware.

Beyond the physical toll, which includes a 2- to 11-fold increase in mortality risk for patients who develop severe SSIs, the financial burden is staggering:

• In the United States: SSIs contribute to more than 400,000 extra hospital days annually, costing the healthcare system an additional $900 million.

• In India: A primary joint replacement is a major investment, but a revision surgery due to infection costs between ₹3 Lakh and ₹6 Lakh in metro cities. Complex premium revisions can skyrocket to ₹6–10 Lakh—roughly 30% to 50% higher than the initial surgery.

The NITK Innovation: How the Dual-Function Coating Works

To interrupt this cycle, Dr. Sudhakar C. Jambagi, an Associate Professor in the Department of Mechanical Engineering at NITK Surathkal, alongside his doctoral student Dr. Deep Shankar, developed a novel bioactive coating. Using an optimized High Velocity Oxy-Fuel (HVOF) thermal spray process, the team managed to bond a specialized antimicrobial layer directly onto the implant material.

“The coating is engineered to deliver localized antimicrobial protection while simultaneously improving mechanical durability, wear resistance, coating adhesion, and bone integration of the implant,” the research team reported.

Comparing Traditional vs. NITK-Coated Implants

By improving osseointegration—the structural and functional connection between living bone and the artificial implant—the coating ensures the joint remains securely anchored. Concurrently, its antimicrobial functionality actively fights off microbial hitchhikers before they can establish a permanent biofilm.

Preclinical Success and the Commercial Pipeline

The innovation has already generated multiple international peer-reviewed publications and has officially been granted a patent. To transition this technology from the lab bench to the patient’s bedside, Dr. Deep Shankar has launched a deep-tech startup.

While preclinical models have yielded highly promising data regarding wear resistance and bacterial reduction compared to commercial implants currently on the market, the team is now charting a course toward human clinical trials.

Expert Perspectives: Cautious Optimism and Regulatory Hurdles

Independent orthopaedic experts view the development as a significant step forward, though they urge a measured perspective regarding timelines.

In a comprehensive review of implant surface modifications, Dr. Volker Alt (University Hospital Regensburg, Germany) and Dr. Antonia F. Chen (Harvard Medical School) noted that while local antimicrobial protection is highly desirable, widespread clinical implementation has been slow.

“Clinical safety of all currently available coatings has been demonstrated, but data have mainly been derived from case series or cohort studies, not from prospective randomized controlled trials,” they emphasized.

Furthermore, the regulatory pathway for such innovations is notoriously strict. Implants featuring active antimicrobial agents are categorized as Class III Medical Devices or Combination Devices. Manufacturers must clear high regulatory hurdles, providing extensive clinical safety data that proves an overall positive benefit-risk ratio before these products can be widely commercialized.

What This Means for Patients

For the estimated 3 crore (30 million) individuals in India suffering from osteoarthritis, only about 1.2 lakh currently undergo knee replacement surgeries each year. Fear of complications, alongside costs, remains a significant barrier.

If successful in clinical trials, this indigenous innovation offers several practical benefits:

• Targeted Defence: Localized antimicrobial action kills bacteria right at the surgical site, reducing reliance on heavy doses of intravenous antibiotics.

• Fewer Surgeries: Stronger bone bonding and fewer infections mean a dramatic reduction in the need for agonizing and expensive revision procedures.

• Affordability: Being an indigenous “Make in India” project, the manufacturing costs are expected to be significantly lower than importing high-end coated alternatives from abroad.

This breakthrough lands at a turning point for India’s biomedical sector. The nation’s bioeconomy has expanded from $10 billion to $80 billion over the past eight years, with projections aiming for $300 billion by 2030. Concurrently, the global antibacterial orthopaedic implant market is growing at a rapid 9.76% compound annual growth rate (CAGR), highlighting a global demand for infection-resistant technologies.

Commenting broadly on the country’s momentum, Dr. Gobardhan Das of NITI Aayog recently noted, “India possesses the scientific prowess and innovation ecosystem necessary to become a global frontrunner in health technologies.”

Limitations and Next Steps

While the milestone is worth celebrating, healthcare consumers should keep the following parameters in mind:

1. Preclinical Status: The technology has proven its efficacy in laboratory and early-stage models but has not yet completed human trials.

2. Regulatory Timeline: Clearing Class III medical device safety protocols typically takes several years.

3. No Immediate Availability: Patients scheduled for joint replacements in the immediate future will still utilize existing standard-of-care options and should consult their orthopaedic surgeon regarding optimal infection-prevention protocols.

The NITK Surathkal coating represents a bold leap toward safer, more durable joint replacements. If it successfully navigates the rigorous gauntlet of clinical trials, it could safely shield millions of future patients from the devastating impacts of joint infections.

Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.

References

• https://health.economictimes.indiatimes.com/news/medical-devices/nitk-researchers-develop-antimicrobial-coating-for-orthopaedic-implants/131366869?utm_source=top_story&utm_medium=homepage